Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Endocavitary Injection of Bone Marrow Derived CD133+ Cells in Ischemic Refractory Cardiomyopathy (RECARDIO Trial)

NCT02059681 is registered in ClinicalTrials.gov with Centro Cardiologico Monzino as lead sponsor.

NCT NCT02059681
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02059681 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Endocavitary Injection of Bone Marrow Derived CD133+ Cells in Ischemic Refractory Cardiomyopathy (RECARDIO Trial)
Lead sponsor
Centro Cardiologico Monzino
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2013
Completion date
February 28, 2022
Enrollment
12 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myocardial ischemia